Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH
Based on 1 Customer Validation
Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH) is a protected glycosylated amino acid and Tn antigen. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH serves as a building block in the solid-phase synthesis of Tn-based cancer vaccine constructs. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH supports solid-phase peptide synthesis.
For research use only. We do not sell to patients.
- Purity : 99.12%
- CAS No.: 120173-57-1
- Formula: C32H36N2O13
- Molecular Weight:656.63
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Fmoc-Ser (O-α-D-GalNAc (OAc)3)-OH serves as a building block in the solid-phase synthesis of Tn-based cancer vaccine constructs. Fmoc-Ser (O-α-D-GalNAc (OAc)3)-OH supports solid-phase peptide synthesis[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 120173-57-1
-
Appearance Solid
-
Molecular Weight 656.63
-
Formula C32H36N2O13
-
Color White to off-white
-
SMILES
O=C(N[C@H](C(O)=O)CO[C@@H](O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O)[C@@H]1NC(C)=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
-
Synonyms
Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH; Fmoc-Ser[GalNAc(Ac)3-α-D]-OH; Fmoc-Ser(Ac3AcNH-α-Gal)-OH
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (152.29 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.81 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.81 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Handling Instructions (2659 KB)
References
[1]. Abdel-Aal AB, et al. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand. J Med Chem. 2012;55(15):6968-6974. [Content Brief]
[2]. Arsequell G, et al. Synthesis, biological evaluation and structural characterization of novel glycopeptide analogues of nociceptin N/OFQ. Org Biomol Chem. 2011;9(17):6133-6142. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5229 mL | 7.6146 mL | 15.2293 mL | 38.0732 mL |
| 5 mM | 0.3046 mL | 1.5229 mL | 3.0459 mL | 7.6146 mL | |
| 10 mM | 0.1523 mL | 0.7615 mL | 1.5229 mL | 3.8073 mL | |
| 15 mM | 0.1015 mL | 0.5076 mL | 1.0153 mL | 2.5382 mL | |
| 20 mM | 0.0761 mL | 0.3807 mL | 0.7615 mL | 1.9037 mL | |
| 25 mM | 0.0609 mL | 0.3046 mL | 0.6092 mL | 1.5229 mL | |
| 30 mM | 0.0508 mL | 0.2538 mL | 0.5076 mL | 1.2691 mL | |
| 40 mM | 0.0381 mL | 0.1904 mL | 0.3807 mL | 0.9518 mL | |
| 50 mM | 0.0305 mL | 0.1523 mL | 0.3046 mL | 0.7615 mL | |
| 60 mM | 0.0254 mL | 0.1269 mL | 0.2538 mL | 0.6346 mL | |
| 80 mM | 0.0190 mL | 0.0952 mL | 0.1904 mL | 0.4759 mL | |
| 100 mM | 0.0152 mL | 0.0761 mL | 0.1523 mL | 0.3807 mL |
Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH Related Classifications
HY-104004 Related Classifications
Powered by Bioz
Keywords
- Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH
- 120173-57-1
- Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH
- Fmoc-Ser[GalNAc(Ac)3-α-D]-OH
- Fmoc-Ser(Ac3AcNH-α-Gal)-OH
- Amino Acid Derivatives
- Drug Intermediate
- solid phase peptide synthesis
- Tn antigen
- lung carcinoma
- cancer vaccine constructs
- stomach carcinoma
- adenocarcinomas
- colon carcinoma
- solid-phase synthesis
- TLR2
- HEK293 cells
- Inhibitor
- inhibitor
- inhibit